Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9HCS2
UPID:
CP4FC_HUMAN
Alternative names:
CYPIVF12
Alternative UPACC:
Q9HCS2; E7ET51; O60389; Q5JPJ7; Q9HCS1
Background:
Cytochrome P450 4F12 (CYPIVF12) is a pivotal enzyme in the metabolism of polyunsaturated fatty acids (PUFAs) and xenobiotics. It catalyzes the hydroxylation of carbon hydrogen bonds, with a preference for the omega-2 position, and is involved in the metabolism of the antihistamine drug ebastine. This enzyme plays a crucial role in converting arachidonate to 18-hydroxy arachidonate and in the epoxidation of PUFAs such as docosapentaenoic and docosahexaenoic acids.
Therapeutic significance:
Understanding the role of Cytochrome P450 4F12 could open doors to potential therapeutic strategies, particularly in the modulation of PUFA metabolism and the detoxification of xenobiotics.